159 related articles for article (PubMed ID: 38129495)
21. p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma.
Wu W; Wei T; Li Z; Zhu J
Int J Med Sci; 2021; 18(14):3197-3205. PubMed ID: 34400889
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
23. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.
Wang T; Lv JH; Zhang XF; Li CJ; Han X; Sun YJ
Int J Cancer; 2010 Jan; 126(2):362-70. PubMed ID: 19609944
[TBL] [Abstract][Full Text] [Related]
24. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
25. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
26. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
[TBL] [Abstract][Full Text] [Related]
29. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells.
Xia X; Ji T; Liu R; Weng Y; Fang Y; Wang Z; Xu H
Eur J Gynaecol Oncol; 2015; 36(6):662-6. PubMed ID: 26775347
[TBL] [Abstract][Full Text] [Related]
31. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
Hu Y; Zhang K; Zhu X; Zheng X; Wang C; Niu X; Jiang T; Ji X; Zhao W; Pang L; Qi Y; Li F; Li L; Xu Z; Gu W; Zou H
Int J Nanomedicine; 2021; 16():2173-2186. PubMed ID: 33758505
[TBL] [Abstract][Full Text] [Related]
33. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
Sun H; Zhou X; Bao Y; Xiong G; Cui Y; Zhou H
Open Biol; 2019 Jul; 9(7):180227. PubMed ID: 31337279
[TBL] [Abstract][Full Text] [Related]
34. Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells.
Hong X; Li S; Li W; Xie M; Wei Z; Guo H; Wei W; Zhang S
Biochem Biophys Res Commun; 2019 Jan; 508(3):986-990. PubMed ID: 30545630
[TBL] [Abstract][Full Text] [Related]
35. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
36. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
37. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
38. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract][Full Text] [Related]
39. Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.
Wang F; Zhang L; Liu J; Zhang J; Xu G
Aging (Albany NY); 2020 Jun; 12(11):11042-11060. PubMed ID: 32516753
[TBL] [Abstract][Full Text] [Related]
40. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
